Skip to main content

Roche may have to pony up more for Genentech if Avastin does well


NEW YORK Genentech’s price tag for Roche Holding may get more expensive, depending on test results for a cancer drug the companies jointly market, according to Bloomberg.

The Basel, Switzerland-based company might have to increase its offer for South San Francisco, Calif.-based Genentech if test results show Avastin working against a larger number of tumors.

If tests are successful, Avastin (bevacizumab) may become a first-choice drug for treating colon tumors. According to Bloomberg.

Roche recently offered $89 per share for the remaining 44 percent of Genentech that it doesn’t already own.

This ad will auto-close in 10 seconds